Patents by Inventor Xu-Yang Zhao

Xu-Yang Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
    Patent number: 7777042
    Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: August 17, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Raymond W. Kosley, Jr., Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-Yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
  • Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
    Patent number: 7550469
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: June 23, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: James A Hendrix, Joseph T Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G Jurcak, Harpal Gill, Franz J Weiberth, Thaddeus Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
  • FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF
    Publication number: 20080139556
    Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.
    Type: Application
    Filed: December 6, 2006
    Publication date: June 12, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Raymond W. KOSLEY, Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
  • Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20070142351
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 21, 2007
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Joseph Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerte, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
  • Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20050107389
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: October 7, 2004
    Publication date: May 19, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Joseph Strupczeski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
  • Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20040030137
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: February 19, 2002
    Publication date: February 12, 2004
    Inventors: James A. Hendrix, Joseph T. Strupczewski, Kenneth J. Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G. Jurcak, Harpal Gill, Franz J. Weiberth, Thaddeus R. Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
  • Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20030229066
    Abstract: The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: February 19, 2002
    Publication date: December 11, 2003
    Inventors: James A. Hendrix, Joseph T. Strupczewski, Kenneth J. Bordeau, Sarah Brooks, Horst Hemmerle, Matthias Urmann, Xu-Yang Zhao, Paul J. Mueller